Sign in to view content

Results from Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity

Rishi P. Singh, MD

Video
Published 2024

Related

Early vs Delayed Pegcetacoplan Treatment for GA Secondary to AMD: 48-Month Results From OAKS, DERBY,and GALE Open-Label Extension
Roger A. Goldberg, MD, MBA
Annual Meeting Talks
2025
Characterizing Real-World Functional Outcomes in Patients with Geographic Atrophy: An IRIS Registry Analysis
Durga Borkar, MD
Annual Meeting Talks
2022
How Do I Decide to Treat Patients with Geographic Atrophy?
Glenn J. Jaffe, MD
Updates from the Field
2024

Category: AMD-Non-Neovascular

See more